Bimekizumab (146–148) can effectively and selectively inhibit IL-17A and IL-17F, being currently in the phase III clinical trial stage for the treatment of various inflammatory diseases, including plaque psoriasis, psoriatic arthritis. This evidence concerns the gene IL17A and psoriasis vulgaris.